HHS Opens an Interim Path for Six Compounded Peptides: What the October 28 Enforcement Policy Changes for Prescribers and Pharmacies, and What It Does Not

On October 28, 2026 the Department of Health and Human Services filed a notice that it does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians that compound drugs from six peptides that are not on the FDA's list of bulk drug substances: BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax. The notice is an interim access policy built on enforcement discretion. It is not an approval, it does not add anything to the 503A bulks list, and HHS says it can be reconsidered if safety signals or product-quality problems appear. For prescribers and compounding pharmacies who have spent two years working around a gray market, it is the first federal signal that a lawful, pharmacy-based path for these peptides exists while the formal rule is written.

This article is educational. It is not medical, legal, or regulatory advice. The policy text is being published in the Federal Register as this article goes live, and several details below are drawn from press reporting rather than the final text. Read the notice itself and confirm your obligations with your counsel and your state board before you change what you prescribe or compound. We will update this article when the published text is available.

What HHS actually did

Compounding pharmacies may generally use only bulk substances that are approved drug components, have a USP or NF monograph, or appear on the FDA's 503A bulks list. None of the six peptides meets those tests, which is why most pharmacies stopped compounding them after the FDA's 2023 categorisation placed them in the group with identified safety concerns. Adding a substance to the bulks list requires notice-and-comment rulemaking, and that process has taken years for every substance that has completed it.

In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted, over the objections of the agency's own reviewers, to recommend six of seven nominated peptides for the list. We covered that meeting and its contested composition at the time. The October 28 notice is the administration's answer to the gap between that vote and a final rule. Instead of waiting, HHS has said it will exercise enforcement discretion for compounders who meet a set of conditions while rulemaking proceeds.

Three features of the notice matter more than the headline.

It is discretion, not permission. The underlying law has not changed. A pharmacy compounding BPC-157 tomorrow is still compounding from a substance that is not on the list; what has changed is that HHS has stated it will not act against that pharmacy if the conditions are met. HHS has also said the document is a draft and is not binding on the agency or the public.
It is interim. The policy runs while the FDA develops the bulks list by rulemaking, and HHS has said it may reconsider if safety signals or quality problems emerge. There is no stated end date, which also means there is no guaranteed runway.
It does not bind the states. Compounding is regulated by state boards of pharmacy, and prescribing by state medical boards. A state that treats these substances as off limits for compounding can continue to do so. Several already do, and a federal enforcement position does not change a state statute.

The six peptides

The notice covers the six substances the July committee recommended: BPC-157, TB-500 (thymosin beta-4 fragment), KPV, MOTS-c, Epitalon, and Semax. It does not cover the seventh nominated substance, and it does not cover any other peptide. Semaglutide and tirzepatide are not part of this policy; the FDA's position on compounded GLP-1 drugs is set by the resolved shortage status of the approved products and is unchanged by this notice. Ipamorelin, CJC-1295, thymosin alpha-1, and the rest of the category 2 list are likewise unaffected. Any claim that peptides are now legal as a class is wrong.

The conditions, as reported

Press reporting and the summaries circulating among compounders describe conditions in five areas. The exact wording will be in the Federal Register text; what follows is the shape of them.

Identity and purity. The pharmacy must certify the identity and purity of the compound it dispenses. In practice that means a certificate of analysis for the bulk substance from the supplier and testing records the pharmacy can produce on request. This is the condition most likely to separate pharmacies that can participate from pharmacies that cannot.
Patient-specific prescriptions. The policy is written for 503A compounding for an identified patient under a valid prescription from a licensed prescriber. It is not a route to stocking, office-use batches, or direct-to-consumer sale.
Labeling. Reports describe a required label statement identifying the product as a compounded drug product, and a limit of a single active ingredient per product. Combination preparations, which are common in the gray market, would fall outside the policy if that reading holds.
Adverse event reporting. The pharmacy must report serious adverse events. This has not previously been required of 503A pharmacies for compounded products, and it is the condition that will need new process at most pharmacies.
Manufacturing standards. Compounding under the applicable USP chapters, with the records to show it.

The notice is reported to be scheduled for Federal Register publication on October 30, with a short public comment period following publication. Clinics and pharmacies that intend to rely on it should read the published text rather than this summary, and should expect the conditions to be enforced as written.

What it means for prescribers

If you have patients asking for BPC-157 or TB-500, the practical change is where a lawful prescription can be filled. Until this week the honest answer in most states was that no pharmacy would compound it. From the effective date, a state-licensed pharmacy that meets the conditions may, in states whose boards allow it.

Four things to check before you write.

Your state. Confirm with your medical board and the pharmacy's board that neither treats the substance as prohibited for compounding. The federal notice does not pre-empt either.
The pharmacy's evidence. Ask for the certificate of analysis for the specific lot your patient will receive, not a generic supplier statement. If the pharmacy cannot produce one, the first condition is not met and your patient is back in the gray market with a prescription label on it.
The indication and the conversation. Nothing in the notice changes the evidence base. The FDA's reviewers concluded that human data for these peptides were insufficient to establish safety and effectiveness, and that conclusion stands. Document the discussion, the patient's understanding that the product is unapproved and compounded, and your reasoning.
Outcomes and adverse events. The reporting duty falls on the pharmacy, but the pharmacy will be relying on you to tell it what happened. Build the follow-up into the visit schedule now.

What it means for compounding pharmacies

Demand will arrive before the Federal Register text does. The pharmacies that benefit will be the ones that can show, on day one, a documented supplier qualification for each bulk peptide, lot-level certificates of analysis, a label template that carries the required statement, single-ingredient formulations, and a written adverse event reporting procedure with someone named to run it. The pharmacies that get hurt will be the ones that treated the notice as a green light and discovered the conditions during an inspection.

Two further points. First, the notice is addressed to state-licensed pharmacies and physicians; the reporting we have seen does not mention 503B outsourcing facilities, so office-use batches of these peptides remain outside the policy unless the published text says otherwise. Second, HHS has said it will reconsider the policy if quality problems emerge. A single contaminated lot, traced to a pharmacy that skipped testing, could close the door for everyone. The industry's interest and the public's interest point the same way here.

How PEPTPlus is set up for this

PEPTPlus was built on the assumption that peptide prescribing would be legitimised on exactly these terms: documented substances, verified pharmacies, and a record of what was dispensed to whom. Every batch listed by a partner pharmacy carries its certificate of analysis, a prescription routes only to a pharmacy licensed in the patient's state, and the platform keeps the provenance from the bulk substance to the shipped product. Practices pay one flat monthly fee and nothing per prescription, so no one on the platform has an incentive to push volume on substances whose evidence base is still being written. We are adding the pieces the notice calls for that were not previously required of 503A pharmacies, starting with adverse event reporting on the order record.

We will update the ingredient register and this article when the Federal Register text is available, and we will note any difference between the reported conditions above and the published ones.